ESC 365 - Pharmacodynamic and pharmacokinetic profiles associated with switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the SWAP-6 study

ESC Professional Premium Access

Pharmacodynamic and pharmacokinetic profiles associated with switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the SWAP-6 study

Session: Antithrombotic therapy in acute coronary syndromes and PCI

Topic: Antiplatelet Drugs

Speaker: Doctor M. Galli (Rome, IT)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Mattia Galli

Sapienza University of Rome, Rome (Italy)

0 follower

6 more presentations in this session

Pattern of dual antiplatelet use and 12-month outcomes stratified by bleeding and ischemic risk in acute coronary syndrome patients undergoing percutaneous coronary intervention

Speaker: Doctor A. Lai (Shatin, HK)

Repeat coronary revascularization in high-risk patients treated with ticagrelor monotherapy after PCI: Insights from the randomized TWILIGHT trial

Speaker: Professor R. Mehran (New York, US)

Mortality with bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome

Speaker: Doctor M. Galli (Rome, IT)

In vitro comparison of platelet aggregation between zalunfiban and selatogrel in healthy donors

Speaker: Mr S. Rikken (Nieuwegein, NL)

Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction

Speaker: Doctor S. Godtfredsen (Aalborg, DK)

Access the full session

Antithrombotic therapy in acute coronary syndromes and PCI

Speakers: Doctor M. Galli, Doctor A. Lai, Professor R. Mehran, Doctor M. Galli, Mr S. Rikken...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources